NCT03251378View on ClinicalTrials.gov

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

December 13, 2022

Study Completion Date

March 30, 2023

Conditions
Advanced Solid TumorsMetastatic Colon CancerMetastatic Breast CancerTriple Negative Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast CarcinomaRectal Cancer
Interventions
DRUG

Fruquintinib (HMPL-013)

Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.

Trial Locations (9)

34952

Hem-Onc Associates of the Treasure Coast, Port Saint Lucie

37232

Vanderbilt Ingram Cancer Center, Nashville

55902

Mayo Clinic Rochester, Rochester

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

85054

Mayo Clinic Arizona, Phoenix

92069

California Cancer Care Associates for Research & Excellence, Inc., San Marcos

95403

St. Joseph Heritage Healthcare, Santa Rosa

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT03251378 - A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | Biotech Hunter | Biotech Hunter